All In Biotech

Drug Trial Radar · NCT04976855

Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use Disorder

A Phase I Double-Blind, Placebo-Controlled Randomized Study to Assess Repeated Doses of INDV-2000 (C4X_3256) up to 28 Days in Healthy Volunteers, and an Open-Label Study of INDV-2000 up to 11 Days in Treatment Seeking Individuals With Opioid Use Disorder

Last checked: Nov 19, 2026Latest source record: Aug 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

64

Actual

Start

Aug 17, 2022

Primary completion

Jul 5, 2023

Study completion Jul 5, 2023

Sponsor

Lead sponsor
Indivior Inc.Industry
Sponsor type
Industry
Collaborators
National Institute on Drug Abuse (NIDA)
First posted
Jul 26, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objectives for the study are: * Part I and Part II: Assess safety and tolerability of repeated doses of INDV-2000 in healthy volunteers. * Part III: Assess the safety and tolerability of repeated doses of INDV-2000 administered alone and with SUBOXONE sublingual (SL) film in an opioid use disorder (OUD) treatment seeking population.

Conditions

  • Healthy Volunteer
  • Opioid-use Disorder

Interventions

  • INDV-2000Drug

    Capsule for oral administration

  • PlaceboDrug

    Capsule for oral administration

  • SUBOXONE® sublingual filmDrug

    Administered either under the tongue (sublingual) or between the gum and cheek (buccal)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part I and Part II: Number of Participants With Adverse EventsTime frame: From first dose of study drug up to 7 days after last dose (up to 14 days in Part I and 35 days in Part II).
  2. Part III: Number of Participants With Adverse EventsTime frame: From first dose of INDV-2000 up to 7 days after last dose (up to 18 days).

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Johns Hopkins University School of Medicine BPRU

    Baltimore, Maryland

  • InSite Clinical Research

    DeSoto, Texas

  • Worldwide Clinical Trials

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.